GRAIL, Inc. (GRAL) is a commercial-stage healthcare company behind Galleri, a multi-cancer early detection blood test that screens for signals from dozens of cancer types in asymptomatic adults over 50. Shares climbed 6.45% on Wednesday, changing hands at $108.69 by midday, up $6.59 from the prior session's close of $102.10. The direction is unambiguously higher, but the cause is not: no verified news or fundamental development was found to explain the advance, which instead appears consistent with a rebound after a steep late-October and November selloff.
No verified news or fundamental catalyst found in company releases, regulatory filings, or wire reports explains today's move. GRAIL has not issued a press release this week beyond routine insider-transaction disclosures, no analyst has published a rating change on Wednesday, and the company's next scheduled disclosure — fourth-quarter results — is not due until February 2027. The most recent substantive events remain the Nov. 4 third-quarter report and the price-target adjustments that followed it last week, all of which predate today's session and were already reflected in Tuesday's close.
The likeliest technical explanation is a relief bounce. From a closing high of $158.92 on Oct. 29, the stock fell to $102.10 by Tuesday, a decline of roughly 36% in fourteen sessions, including drops of 9.75% on Oct. 30, 17.08% on Nov. 5, and 8.88% on Nov. 16. Sharp declines of that magnitude in a stock with a beta near 2.9 frequently produce short-covering and dip-buying bounces. A widely syndicated investment commentary piece published overnight on GRAIL's long-term FDA and margin path may also have nudged retail attention, though its content was largely a recap of the Nov. 4 call and is too modest to account for a 6.45% gain alone. Despite today's move, the stock remains below its 10-day and 20-day average closing levels.
GRAIL's third-quarter report on Nov. 4 showed screening revenue of $37.5 million, up about 3.7% year over year and short of consensus expectations, alongside a net loss of $103.6 million. Management disclosed a promotional price cut that reduced average selling price to roughly $660 per test — a deliberate trade of near-term margin for volume — and confirmed that a legacy royalty to ILMN resumes in late December 2026. Those disclosures, not today's tape, drove the November drawdown.
The bullish counterweight is regulatory. An FDA advisory panel voted in September in favor of Galleri's safety, effectiveness, and benefit-risk profile, and management expects a final premarket approval decision early in the first quarter of 2027, alongside reimbursement expectations of $500 to $600 per test and active commercial payer discussions. Consensus ratings remain at Buy with an average price target well above the current price, though estimates range widely, reflecting genuine disagreement on the ramp.
Turnover has thinned during the selloff. The stock's three-month average volume is roughly 1.0 million shares, yet a dozen of the past twenty sessions traded fewer than 400,000 shares, with Tuesday's 272,000 shares among the lightest. Thin participation amplifies price swings in both directions and makes a 6.45% move easier to achieve without a news catalyst.
The move appeared idiosyncratic rather than sector-driven. Today's gain came without a corresponding company announcement, and the stock is still 33% below its late-October peak and roughly 35% below its 52-week high of $166.48, while sitting well above the 52-week low of $41.50. Technically, shares pushed back above the $105–$107 zone that capped Tuesday's session, but the $100 round number — tested repeatedly since mid-November — remains the level to watch on the downside.
The score runs from 0, meaning no meaningful news and a move entirely normal for the stock, to 100, meaning transformative news accompanied by a rare, extreme price move. Here, the verified news component is weak: no release, filing, or rating change accompanied the gain, only background commentary on an FDA decision still months away. The price component is similarly unremarkable. At 6.45%, the move was roughly 1.4 times the stock's average absolute daily change of 4.7% over the past 60 sessions, and twelve sessions in that window produced equal or larger swings, including moves of 33.7% and 23.1%. With both components subdued, the score lands at 11 out of 100.
The dominant scheduled event is the FDA's decision on the Galleri premarket approval application, which management expects early in the first quarter of 2027; the label's scope and any post-approval study requirements will matter as much as the approval itself. Fourth-quarter results, due around mid-February, will be scrutinized for test volume growth against the 24% year-over-year increase posted in the third quarter, for average selling price trends under the promotional pricing, and for cash burn against a $788.7 million balance that management says funds operations into 2029. The resumption of the Illumina royalty in late December adds a known cost headwind. On the commercial side, progress in securing private payer coverage and any Medicare pathway news are the key variables for the bull case. Risks include slower-than-expected reimbursement, competitive pressure from cheaper laboratory-developed tests, insider selling that has weighed on sentiment, and the stock's tendency toward double-digit percentage swings around binary regulatory news.
Tickeron offers hundreds of AI trading bots covering thousands of tickers, but only the strongest performers under current market conditions earn a place in the curated Trending AI Robots section. The bots differ by strategy, timeframe, performance metrics, and the symbols they trade, so the lineup rotates as market conditions shift. For a name as volatile as GRAL, reviewing how automated strategies have handled recent sessions can add useful perspective to your own research.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
The 10-day RSI Oscillator for GRAL moved out of overbought territory on October 30, 2026. This could be a sign that the stock is shifting from an upward trend to a downward trend. Traders may want to look at selling the stock or buying put options. Tickeron's A.I.dvisor looked at 22 instances where the indicator moved out of the overbought zone. In 22 of the 22 cases the stock moved lower in the days that followed. This puts the odds of a move down at 90%.
The Momentum Indicator moved below the 0 level on November 05, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on GRAL as a result. In 37 of 43 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 86%.
The Moving Average Convergence Divergence Histogram (MACD) for GRAL turned negative on November 02, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 20 similar instances when the indicator turned negative. In 19 of the 20 cases the stock turned lower in the days that followed. This puts the odds of success at 90%.
GRAL moved below its 50-day moving average on November 13, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for GRAL crossed bearishly below the 50-day moving average on November 17, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 4 of 7 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 57%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where GRAL declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 78%.
GRAL broke above its upper Bollinger Band on October 27, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for GRAL entered a downward trend on November 10, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 8 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Following a +7.51% 3-day Advance, the price is estimated to grow further. Considering data from situations where GRAL advanced for three days, in 116 of 133 cases, the price rose further within the following month. The odds of a continued upward trend are 87%.
The Tickeron Price Growth Rating for this company is 38 (best 1 - 100 worst), indicating steady price growth. GRAL’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 43 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.133) is normal, around the industry mean (67.298). P/E Ratio (-12.533) is within average values for comparable stocks, (4.239). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (3.473). Dividend Yield (0.000) settles around the average of (0.002) among similar stocks. P/S Ratio (18.248) is also within normal values, averaging (9.775).
The Tickeron SMR rating for this company is 94 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is 96 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. GRAL’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 87, placing this stock worse than average.
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Industry MedicalSpecialties